Newsroom

Press Releases



New GMP-manufactured Cas9 Protein Enables Clinical Genome Editing Research

Gibco CTS TrueCut Cas9 Protein supports use of genome editing for research and manufacturing applications, including CAR T-cell therapy research

As researchers using genome editing tools move from basic research to clinical settings, high-quality ancillary materials and documentation are critical. To help researchers meet stringent quality requirements, Thermo Fisher Scientific introduced the new GMP-manufactured Gibco CTS TrueCut Cas9 Protein. TrueCut Cas9 proteins are manufactured with United States Pharmacopeia standards in mind, including traceability documentation, aseptic manufacturing and safety testing.

The new GMP-manufactured Gibco CTS TrueCut Cas9 Protein from Thermo Fisher Scientific supports use of genome editing for research and manufacturing applications, including CAR T-cell therapy research. (Photo: Business Wire)

The new GMP-manufactured Gibco CTS TrueCut Cas9 Protein from Thermo Fisher Scientific supports use of genome editing for research and manufacturing applications, including CAR T-cell therapy research. (Photo: Business Wire)

Gibco CTS TrueCut Cas9 Protein provides consistent high-editing efficiency in all tested cell lines and greater than 90% efficiency in human primary T-cells, making it a compelling solution for CAR T-cell therapy research using CRISPR-Cas9 genome editing. With the addition of a GMP-manufactured Cas9 protein and the recently launched Gibco CTS Xenon Electroporation System, Thermo Fisher can now support researchers across the autologous T-cell workflow.

"As genome editing quality and regulatory requirements continue to evolve, we are focused on providing solutions to meet scientists' needs as they transition from the bench to the clinic," said Brandon Pence, vice president and general manager of cell biology at Thermo Fisher Scientific. "By adding the Gibco CTS TrueCut Cas9 Protein to our portfolio of genome editing solutions, we can now support scientists in their journey to develop personalized CAR T-cell therapeutics."

The Gibco CTS TrueCut Cas9 Protein is part of Thermo Fisher's Cell Therapy Systems (CTS) product line, a comprehensive portfolio of GMP-manufactured products supported by traceability documentation. This product line is designed to work synergistically across the entire workflow, from cell isolation/activation to cell engineering and expansion, to address cell therapy developers' manufacturing needs.

To learn more about the Gibco CTS TrueCut Cas9 Protein, visit thermofisher.com/ctscas9.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Media contact information:

Kristin Blake
760-637-1166
kristin.blake@thermofisher.com

Jen Heady
413-237-5141
jheady@greenough.biz

Source: Thermo Fisher

If you have any questions regarding this Press Release, please email us at media.relations@thermofisher.com